Human Insulin Market By Product Type, By Indication By Type of Insulin By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

Human Insulin Market

The human insulin market was valued at $17.1 billion in 2023 and is projected to reach $24.0 billion by 2033, growing at a CAGR of 3.4% from 2024 to 2033.

Human insulin is a synthetic mimic of the natural peptide hormone, which is synthesized in laboratory settings inside E. coli bacteria. It exists in two forms: a short-acting regular form and an intermediate-acting form known as neural protamine Hagedorn insulin. Human insulin replaces the naturally produced insulin inside the body and regulates the glucose levels in the blood.

A key driver of the human insulin market is increase in the prevalence of diabetes globally. In addition, human insulin is experiencing a surge in demand from patients and medical practitioners as compared to animal insulin owing to its high efficacy and minimal risk of allergic reactions. The latest trend in the human insulin market is the inclination of patients toward biosimilar products owing to their comparable efficacy and high cost-effectiveness.

However, the presence of other alternatives such as oral medications and non-insulin injectables, including GLP-1 receptor agonists, offers a significant competition to human insulin. Moreover, the introduction of human insulin into the market is a complex & time-consuming process due to the lengthy regulatory approval procedure at different stages, which include pre-clinical stages, clinical trials, and post-market safety monitoring. This delays the availability of the protein, thereby limiting the development of the market. On the contrary, the integration of data-driven approaches such as AI and machine learning is expected to speed up production efficiency by optimizing the production parameters and predicting product yields.

Segment Review

The human insulin market is segmented into product type, indication, type of insulin, distribution channel, and region. On the basis of product type, the market is divided into pens, syringes, and others. As per indication, it is classified into type 1 diabetes, type 2 diabetes, and gestational diabetes. Depending on type of insulin, it is categorized into rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and others. According to distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product type, the pens segment dominated the market in 2023.

As per indication, the type-1 diabetes segment acquired high stakes in the market in 2023.

Depending on type of insulin, the rapid-acting insulin segment garnered a high market share in 2023.

According to distribution channel, the drug stores & retail pharmacies segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The major players operating in the global human insulin market include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Pfizer, Biocon, Wockhardt, MannKind Corporation, Tonghua Dongbao Pharmaceutical Co., Ltd., Medtronic, and Lupin. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

Pens
Syringes
Others

By Indication

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

By Type Of Insulin

Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others

By Distribution Channel

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Eli Lilly and Company
Sanofi
Novo Nordisk A/S
Pfizer
Biocon
Wockhardt
MannKind Corporation
Tonghua Dongbao Pharmaceutical Co., Ltd.
Medtronic
Lupin

Product Code: A00321

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: HUMAN INSULIN MARKET, BY PRODUCT TYPE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Product Type
4.2. Pens
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Syringes
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
4.4. Others
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country

CHAPTER 5: HUMAN INSULIN MARKET, BY INDICATION

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Indication
5.2. Type 1 Diabetes
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Type 2 Diabetes
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
5.4. Gestational Diabetes
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country

CHAPTER 6: HUMAN INSULIN MARKET, BY TYPE OF INSULIN

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Type of Insulin
6.2. Rapid-acting Insulin
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
6.3. Short-acting Insulin
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
6.4. Intermediate-acting Insulin
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
6.5. Others
- 6.5.1. Key Market Trends, Growth Factors and Opportunities
- 6.5.2. Market Size and Forecast, By Region
- 6.5.3. Market Share Analysis, By Country

CHAPTER 7: HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL

7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Distribution Channel
7.2. Hospital Pharmacies
- 7.2.1. Key Market Trends, Growth Factors and Opportunities
- 7.2.2. Market Size and Forecast, By Region
- 7.2.3. Market Share Analysis, By Country
7.3. Drug Stores And Retail Pharmacies
- 7.3.1. Key Market Trends, Growth Factors and Opportunities
- 7.3.2. Market Size and Forecast, By Region
- 7.3.3. Market Share Analysis, By Country
7.4. Online Providers
- 7.4.1. Key Market Trends, Growth Factors and Opportunities
- 7.4.2. Market Size and Forecast, By Region
- 7.4.3. Market Share Analysis, By Country

CHAPTER 8: HUMAN INSULIN MARKET, BY REGION

8.1. Market Overview
- 8.1.1 Market Size and Forecast, By Region
8.2. North America
- 8.2.1. Key Market Trends and Opportunities
- 8.2.2. Market Size and Forecast, By Product Type
- 8.2.3. Market Size and Forecast, By Indication
- 8.2.4. Market Size and Forecast, By Type of Insulin
- 8.2.5. Market Size and Forecast, By Distribution Channel
- 8.2.6. Market Size and Forecast, By Country
- 8.2.7. U.S. Human Insulin Market
  - 8.2.7.1. Market Size and Forecast, By Product Type
  - 8.2.7.2. Market Size and Forecast, By Indication
  - 8.2.7.3. Market Size and Forecast, By Type of Insulin
  - 8.2.7.4. Market Size and Forecast, By Distribution Channel
- 8.2.8. Canada Human Insulin Market
  - 8.2.8.1. Market Size and Forecast, By Product Type
  - 8.2.8.2. Market Size and Forecast, By Indication
  - 8.2.8.3. Market Size and Forecast, By Type of Insulin
  - 8.2.8.4. Market Size and Forecast, By Distribution Channel
- 8.2.9. Mexico Human Insulin Market
  - 8.2.9.1. Market Size and Forecast, By Product Type
  - 8.2.9.2. Market Size and Forecast, By Indication
  - 8.2.9.3. Market Size and Forecast, By Type of Insulin
  - 8.2.9.4. Market Size and Forecast, By Distribution Channel
8.3. Europe
- 8.3.1. Key Market Trends and Opportunities
- 8.3.2. Market Size and Forecast, By Product Type
- 8.3.3. Market Size and Forecast, By Indication
- 8.3.4. Market Size and Forecast, By Type of Insulin
- 8.3.5. Market Size and Forecast, By Distribution Channel
- 8.3.6. Market Size and Forecast, By Country
- 8.3.7. Germany Human Insulin Market
  - 8.3.7.1. Market Size and Forecast, By Product Type
  - 8.3.7.2. Market Size and Forecast, By Indication
  - 8.3.7.3. Market Size and Forecast, By Type of Insulin
  - 8.3.7.4. Market Size and Forecast, By Distribution Channel
- 8.3.8. France Human Insulin Market
  - 8.3.8.1. Market Size and Forecast, By Product Type
  - 8.3.8.2. Market Size and Forecast, By Indication
  - 8.3.8.3. Market Size and Forecast, By Type of Insulin
  - 8.3.8.4. Market Size and Forecast, By Distribution Channel
- 8.3.9. UK Human Insulin Market
  - 8.3.9.1. Market Size and Forecast, By Product Type
  - 8.3.9.2. Market Size and Forecast, By Indication
  - 8.3.9.3. Market Size and Forecast, By Type of Insulin
  - 8.3.9.4. Market Size and Forecast, By Distribution Channel
- 8.3.10. Italy Human Insulin Market
  - 8.3.10.1. Market Size and Forecast, By Product Type
  - 8.3.10.2. Market Size and Forecast, By Indication
  - 8.3.10.3. Market Size and Forecast, By Type of Insulin
  - 8.3.10.4. Market Size and Forecast, By Distribution Channel
- 8.3.11. Spain Human Insulin Market
  - 8.3.11.1. Market Size and Forecast, By Product Type
  - 8.3.11.2. Market Size and Forecast, By Indication
  - 8.3.11.3. Market Size and Forecast, By Type of Insulin
  - 8.3.11.4. Market Size and Forecast, By Distribution Channel
- 8.3.12. Rest of Europe Human Insulin Market
  - 8.3.12.1. Market Size and Forecast, By Product Type
  - 8.3.12.2. Market Size and Forecast, By Indication
  - 8.3.12.3. Market Size and Forecast, By Type of Insulin
  - 8.3.12.4. Market Size and Forecast, By Distribution Channel
8.4. Asia-Pacific
- 8.4.1. Key Market Trends and Opportunities
- 8.4.2. Market Size and Forecast, By Product Type
- 8.4.3. Market Size and Forecast, By Indication
- 8.4.4. Market Size and Forecast, By Type of Insulin
- 8.4.5. Market Size and Forecast, By Distribution Channel
- 8.4.6. Market Size and Forecast, By Country
- 8.4.7. Japan Human Insulin Market
  - 8.4.7.1. Market Size and Forecast, By Product Type
  - 8.4.7.2. Market Size and Forecast, By Indication
  - 8.4.7.3. Market Size and Forecast, By Type of Insulin
  - 8.4.7.4. Market Size and Forecast, By Distribution Channel
- 8.4.8. China Human Insulin Market
  - 8.4.8.1. Market Size and Forecast, By Product Type
  - 8.4.8.2. Market Size and Forecast, By Indication
  - 8.4.8.3. Market Size and Forecast, By Type of Insulin
  - 8.4.8.4. Market Size and Forecast, By Distribution Channel
- 8.4.9. India Human Insulin Market
  - 8.4.9.1. Market Size and Forecast, By Product Type
  - 8.4.9.2. Market Size and Forecast, By Indication
  - 8.4.9.3. Market Size and Forecast, By Type of Insulin
  - 8.4.9.4. Market Size and Forecast, By Distribution Channel
- 8.4.10. Australia Human Insulin Market
  - 8.4.10.1. Market Size and Forecast, By Product Type
  - 8.4.10.2. Market Size and Forecast, By Indication
  - 8.4.10.3. Market Size and Forecast, By Type of Insulin
  - 8.4.10.4. Market Size and Forecast, By Distribution Channel
- 8.4.11. South Korea Human Insulin Market
  - 8.4.11.1. Market Size and Forecast, By Product Type
  - 8.4.11.2. Market Size and Forecast, By Indication
  - 8.4.11.3. Market Size and Forecast, By Type of Insulin
  - 8.4.11.4. Market Size and Forecast, By Distribution Channel
- 8.4.12. Rest of Asia-Pacific Human Insulin Market
  - 8.4.12.1. Market Size and Forecast, By Product Type
  - 8.4.12.2. Market Size and Forecast, By Indication
  - 8.4.12.3. Market Size and Forecast, By Type of Insulin
  - 8.4.12.4. Market Size and Forecast, By Distribution Channel
8.5. LAMEA
- 8.5.1. Key Market Trends and Opportunities
- 8.5.2. Market Size and Forecast, By Product Type
- 8.5.3. Market Size and Forecast, By Indication
- 8.5.4. Market Size and Forecast, By Type of Insulin
- 8.5.5. Market Size and Forecast, By Distribution Channel
- 8.5.6. Market Size and Forecast, By Country
- 8.5.7. Brazil Human Insulin Market
  - 8.5.7.1. Market Size and Forecast, By Product Type
  - 8.5.7.2. Market Size and Forecast, By Indication
  - 8.5.7.3. Market Size and Forecast, By Type of Insulin
  - 8.5.7.4. Market Size and Forecast, By Distribution Channel
- 8.5.8. Saudi Arabia Human Insulin Market
  - 8.5.8.1. Market Size and Forecast, By Product Type
  - 8.5.8.2. Market Size and Forecast, By Indication
  - 8.5.8.3. Market Size and Forecast, By Type of Insulin
  - 8.5.8.4. Market Size and Forecast, By Distribution Channel
- 8.5.9. South Africa Human Insulin Market
  - 8.5.9.1. Market Size and Forecast, By Product Type
  - 8.5.9.2. Market Size and Forecast, By Indication
  - 8.5.9.3. Market Size and Forecast, By Type of Insulin
  - 8.5.9.4. Market Size and Forecast, By Distribution Channel
- 8.5.10. Rest of LAMEA Human Insulin Market
  - 8.5.10.1. Market Size and Forecast, By Product Type
  - 8.5.10.2. Market Size and Forecast, By Indication
  - 8.5.10.3. Market Size and Forecast, By Type of Insulin
  - 8.5.10.4. Market Size and Forecast, By Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

10.1. Eli Lilly And Company
- 10.1.1. Company Overview
- 10.1.2. Key Executives
- 10.1.3. Company Snapshot
- 10.1.4. Operating Business Segments
- 10.1.5. Product Portfolio
- 10.1.6. Business Performance
- 10.1.7. Key Strategic Moves and Developments
10.2. Sanofi
- 10.2.1. Company Overview
- 10.2.2. Key Executives
- 10.2.3. Company Snapshot
- 10.2.4. Operating Business Segments
- 10.2.5. Product Portfolio
- 10.2.6. Business Performance
- 10.2.7. Key Strategic Moves and Developments
10.3. Novo Nordisk A/S
- 10.3.1. Company Overview
- 10.3.2. Key Executives
- 10.3.3. Company Snapshot
- 10.3.4. Operating Business Segments
- 10.3.5. Product Portfolio
- 10.3.6. Business Performance
- 10.3.7. Key Strategic Moves and Developments
10.4. Pfizer
- 10.4.1. Company Overview
- 10.4.2. Key Executives
- 10.4.3. Company Snapshot
- 10.4.4. Operating Business Segments
- 10.4.5. Product Portfolio
- 10.4.6. Business Performance
- 10.4.7. Key Strategic Moves and Developments
10.5. Biocon
- 10.5.1. Company Overview
- 10.5.2. Key Executives
- 10.5.3. Company Snapshot
- 10.5.4. Operating Business Segments
- 10.5.5. Product Portfolio
- 10.5.6. Business Performance
- 10.5.7. Key Strategic Moves and Developments
10.6. Wockhardt
- 10.6.1. Company Overview
- 10.6.2. Key Executives
- 10.6.3. Company Snapshot
- 10.6.4. Operating Business Segments
- 10.6.5. Product Portfolio
- 10.6.6. Business Performance
- 10.6.7. Key Strategic Moves and Developments
10.7. MannKind Corporation
- 10.7.1. Company Overview
- 10.7.2. Key Executives
- 10.7.3. Company Snapshot
- 10.7.4. Operating Business Segments
- 10.7.5. Product Portfolio
- 10.7.6. Business Performance
- 10.7.7. Key Strategic Moves and Developments
10.8. Tonghua Dongbao Pharmaceutical Co., Ltd.
- 10.8.1. Company Overview
- 10.8.2. Key Executives
- 10.8.3. Company Snapshot
- 10.8.4. Operating Business Segments
- 10.8.5. Product Portfolio
- 10.8.6. Business Performance
- 10.8.7. Key Strategic Moves and Developments
10.9. Medtronic
- 10.9.1. Company Overview
- 10.9.2. Key Executives
- 10.9.3. Company Snapshot
- 10.9.4. Operating Business Segments
- 10.9.5. Product Portfolio
- 10.9.6. Business Performance
- 10.9.7. Key Strategic Moves and Developments
10.10. Lupin
- 10.10.1. Company Overview
- 10.10.2. Key Executives
- 10.10.3. Company Snapshot
- 10.10.4. Operating Business Segments
- 10.10.5. Product Portfolio
- 10.10.6. Business Performance
- 10.10.7. Key Strategic Moves and Developments